HealthcareServices

Global Pernicious Anemia Diagnosis And Treatment Market Performance Report: Global Trends 2026–2030

March 2, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the pernicious anemia diagnosis and treatment market from 2026–2035 with trusted insights from The Business Research Company

What upper market value could the Pernicious Anemia Diagnosis And Treatment Market reach by 2030 starting from 2026 levels?

The market for the diagnosis and treatment of pernicious anemia has experienced significant expansion over recent years. This market is projected to expand from $1.51 billion in 2025 to $1.62 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 6.8%. Historical growth in this sector has been driven by factors such as a high occurrence of hospital-acquired infections, continued dependence on traditional IV catheters, an expanding patient base needing IV therapy, a scarcity of sophisticated safety catheters, and a disjointed healthcare infrastructure.

The pernicious anemia diagnosis and treatment market size is anticipated to demonstrate strong expansion in the upcoming years. It is projected to reach $2.09 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.6%. This projected growth can be attributed to enhancements in safety iv catheter technologies, the increasing uptake of smart and antimicrobial catheters, the broadening of home healthcare services, an increasing preference for integrated/closed iv systems, and a rising demand for minimally invasive therapy administration. Notable trends during the forecast period include the increasing adoption of ai-based catheter insertion guidance systems, a rising utilization of cloud-based patient monitoring for iv therapy, the ongoing development of antimicrobial and smart catheters, greater integration of iot-enabled devices for iv monitoring, and the increasing implementation of smart manufacturing for peripheral iv catheters.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24360&type=smp

Which Drivers Are Influencing Long-Term Growth In The Pernicious Anemia Diagnosis And Treatment Market?

The increasing occurrence of vitamin B12 deficiency is anticipated to fuel expansion in the pernicious anemia diagnosis and treatment market in the future. This deficiency arises when the body does not possess sufficient vitamin B12 for the adequate creation of red blood cells, resulting in signs like tiredness, feebleness, and neurological problems. The surge in vitamin B12 deficiency is linked to the growing popularity of plant-based diets, which frequently do not provide enough natural B12 sources and can cause insufficient intake without appropriate supplementation. The presence of vitamin B12 deficiency facilitates the diagnosis and treatment of pernicious anemia because diminished B12 levels directly hinder red blood cell generation, prompting medical professionals to utilize B12 supplementation as a key and successful therapeutic approach. For example, a report from February 2023 by the National Health Service (NHS), a UK-based government health organization, indicated that vitamin B12 and folate deficiencies are more common among older adults, impacting approximately 1 in 10 individuals 75 years of age or older and 1 in 20 of those 65 to 74 years of age. Consequently, the growing occurrence of vitamin B12 deficiency is propelling the expansion of the pernicious anemia diagnosis and treatment market.

Which Segments Are Driving Activity In The Pernicious Anemia Diagnosis And Treatment Market?

The pernicious anemia diagnosis and treatment market covered in this report is segmented –

1) By Type: Complete Blood Count Test, Vitamin B12 Deficiency test, Intrinsic Factor Deficiency Test

2) By Treatment: Vitamin B12 Injections, Vitamin B12 Pills, Spray

3) By Route Of Administration: Injection, Oral, Intranasal

4) By End-User: Hospitals, Clinics, Diagnostic Centres, Other End-users

Subsegments:

1) By Complete Blood Count (CBC) Test: Red Blood Cell Count, Hemoglobin Concentration, Hematocrit Levels, Mean Corpuscular Volume (MCV), White Blood Cell Count, Platelet Count

2) By Vitamin B12 Deficiency Test: Serum Vitamin B12 Test, Methylmalonic Acid (MMA) Test, Homocysteine Test, Holotranscobalamin (Active B12) Test

3) By Intrinsic Factor Deficiency Test: Intrinsic Factor Antibody Test, Parietal Cell Antibody Test, Schilling Test, Gastrin Level Test

Which Trends Are Influencing The Development Of The Pernicious Anemia Diagnosis And Treatment Market?

Major companies in the pernicious anemia diagnosis and treatment market are prioritizing the development of innovative solutions, including vitamin B12 maintenance therapy solutions, to enhance patient adherence and long-term disease management. Vitamin B12 maintenance therapy solutions involve consistent, ongoing supplementation through methods like oral tablets, injections, or nasal sprays to sustain adequate B12 levels and prevent the return of deficiency-related symptoms. For instance, in February 2024, Lupin Pharmaceuticals Inc., an India-based pharmaceutical company, launched cyanocobalamin nasal spray, 500 mcg/spray, presenting a non-invasive alternative for vitamin B12 supplementation. This nasal spray offers a convenient and effective method for patients with pernicious anemia who struggle with oral vitamin B12 forms. It helps improve B12 absorption and supports the management of vitamin B12 deficiency, ultimately leading to enhanced patient compliance and better treatment outcomes.

Which Leading Companies Dominate The Pernicious Anemia Diagnosis And Treatment Market Share?

Major companies operating in the pernicious anemia diagnosis and treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Sanofi S.A., Thermo Fisher Scientific Inc., GSK plc, Takeda Pharmaceutical Company Limited, Lupin Limited, Eli Lilly and Company, DSM Nutritional Products AG, Bio-Rad Laboratories Inc., CSL Vifor Pharma, Par Pharmaceutical Companies Inc., AdvaCare Pharma, Monobind Inc., Merck KGaA, Abbott Laboratories, Siemens Healthineers AG, Ortho Clinical Diagnostics Inc., Quest Diagnostics Incorporated, Bio-Techne Corporation

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/pernicious-anemia-diagnosis-and-treatment-global-market-report

How Does The Pernicious Anemia Diagnosis And Treatment Market Perform Across Major Global Regions?

North America was the largest region in the pernicious anemia diagnosis and treatment market in 2025. The regions covered in the pernicious anemia diagnosis and treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Pernicious Anemia Diagnosis And Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24360&type=smp

Browse Through More Reports Similar to the Global Pernicious Anemia Diagnosis And Treatment Market 2026, By The Business Research Company

Iron Deficiency Injectable Market Report 2026

https://www.thebusinessresearchcompany.com/report/iron-deficiency-injectable-global-market-report

Chemotherapy Induced Anemia Market Report 2026

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report

Aplastic Anemia Market Report 2026

https://www.thebusinessresearchcompany.com/report/aplastic-anemia-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795